Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor

International Journal of Gynecological Cancer

Volumn 21, Issue 7, 2011, Pages 1241-1247

  Yigit, Refika ^a   Massuger, Leon F A G ^a   Zusterzeel, Petra L M ^a   Pots, Jeanette ^b   Figdor, Carl G ^b   Torensma, Ruurd ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cyst fluid; Cytokines; Immunosuppression; Ovarian tumors

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CYST FLUID; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; CARCINOMA; CHEMISTRY; MIDDLE AGED; OVARY; OVARY TUMOR; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA; CYST FLUID; CYTOKINES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; TH1 CELLS; TH2 CELLS;

EID: 84856071150     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182289ab1     Document Type: Article

References (25)

1. Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-443.
2. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518. (Pubitemid 38529752)
3. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18(suppl 2):S19-S32. (Pubitemid 40188615)
4. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61:152-163. (Pubitemid 351218874)
5. Berek JS, Chung C, Kaldi K, et al. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164:1038-1042.
6. Torres MP, Ponnusamy MP, Lakshmanan I, et al. Immunopathogenesis of ovarian cancer. Minerva Med. 2009;100:385-400.
7. Giuntoli RL, Webb TJ, Zoso A, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009;29:2875-2884.
8. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949. (Pubitemid 39273735)
9. Kryczek I, Wei S, Zou L, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol. 2006;177:40-44. (Pubitemid 43939113)
10. Norgaard P, Hougaard S, Poulsen HS, et al. Transforming growth factor beta and cancer. Cancer Treat Rev. 1995;21:367-403.
11. Vergara D, Merlot B, Lucot JP, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291:59-66.
12. Qin XJ, Shi HZ, Deng JM, et al. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res. 2009;15:2231-2237.
13. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 2010;11:1133-1146.
14. Penson RT, Kronish K, Duan Z, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 2000;10:33-41. (Pubitemid 30219476)
15. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005;65:10794-10800. (Pubitemid 41713347)
16. van der Zee AG, de Cuyper EM, Limburg PC, et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer. 1995;75:1004-1009.
17. Xu L, Pathak PS, Fukumura D. Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3′-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res. 2004;10:701-707. (Pubitemid 38174009)
18. Fasciani A, D'Ambrogio G, Bocci G, et al. Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril. 2001;75:1218-1221. (Pubitemid 32522624)
19. Ivarsson K, Runesson E, Sundfeldt K, et al. The chemotactic cytokine interleukin8-a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncol. 1998;71:420-423. (Pubitemid 29022330)
20. Milne K, Kobel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE. 2009;4:e6412.
21. Darai E, Detchev R, Hugol D, et al. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod. 2003;18:1681-1685. (Pubitemid 36958050)
22. Lou W, Ni Z, Dyer K, et al. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate. 2000;42:239-242. (Pubitemid 30080423)
23. Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250:607-610. (Pubitemid 19171418)
24. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 1997;57:141-146. (Pubitemid 27020343)
25. Smith PC, Hobisch A, Lin DL, et al. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001;12:33-40. (Pubitemid 32294585)